FIT (First-line Indolent Trial)

Quick Answer

FIT (the First-line Indolent Trial; Morschhauser et al., J Clin Oncol 2008) was the phase 3 randomized trial that established ⁹⁰Y-ibritumomab tiuxetan (Zevalin) as consolidation after first remission in advanced-stage follicular lymphoma. A single course of this anti-CD20 radioimmunotherapy (RIT) given to patients in remission after first-line chemotherapy markedly prolonged progression-free survival and converted many partial responses to complete responses. It is the landmark trial for radioimmunotherapy — the beta-emitting antibody-targeted therapy of hematologic nuclear medicine.

The trial

Design: phase 3, 414 patients with advanced-stage follicular lymphoma in complete or partial remission after first-line chemotherapy. Randomized to a single course of ⁹⁰Y-ibritumomab tiuxetan consolidation versus no further treatment (observation). Primary endpoint: progression-free survival.

Key result

RIT consolidation prolonged median PFS substantially (~37 vs ~14 months) and improved response quality — a large fraction of partial responders converted to complete response. The main toxicity was transient, reversible cytopenias (the expected marrow effect of a systemic beta-emitting radioimmunoconjugate). The benefit held across chemotherapy backgrounds used at the time.

Why it mattered

FIT gave level-1 evidence that a single antibody-targeted radionuclide course can meaningfully deepen and prolong first remission in follicular lymphoma, validating radioimmunotherapy as an effective, well-tolerated consolidation strategy. It remains the defining trial of RIT in nuclear medicine, illustrating the targeted beta-emitter–on-an-antibody principle that parallels the small-molecule theranostics used elsewhere in the field.

Context & caveats

FIT predates widespread rituximab maintenance; in the modern immunochemotherapy era (rituximab-containing induction and maintenance), RIT's relative role has narrowed, and Zevalin availability varies by region. The concept — CD20-targeted radioimmunotherapy — remains important for teaching and for selected relapsed/refractory settings.

Self-Check

Key References

• Morschhauser F, et al. Phase III trial of consolidation therapy with yttrium-90–ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma (FIT). J Clin Oncol 2008;26:5156–5164. doi:10.1200/JCO.2008.17.2015